Agenda

08:00
Registration Starts & Morning Coffee

09:00
Chairperson’s Opening Remarks

Sekar Sakthivel, Principal: R&D Programme Management & Business Development || Singapore Bioimaging Consortium || A*STAR Research Entities, Singapore


DAY ONE OPENING PLENARY SESSIONS
Bioprocess & Technology and Cell and Gene Therapy Conferences


09:10
Keynote Panel:
Bringing Together Trends in Process Technology, 4.0 And New Therapy Development

  • Collaborative efforts in promoting Pharma 4.0
  • Technological and commercial drivers
  • Scaling up production of CGT – What do we need in the region?
  • Digital strategy and preparing workforce for pharma 4.0
  • Next generation tech tools for manufacturing regenerative medicines
  • Innovation in Process, and Investment Trends in Tech
  • Machine learning and digital transformation in the industry
  • What to consider, upgrading facilities for new therapies

Moderator:
Sekar Sakthivel, Principal: R&D Programme Management & Business Development || Singapore Bioimaging Consortium || A*STAR Research Entities, Singapore

Panellists:
Li Yi PhD, Chief Scientific Officer, Xiangxue Life Sciences, China
Ravi Kiran, Director of Quality, Tessa Therapeutics, Singapore
Tulip Nuwal, Head – Biopharma Business Operations and Excellence, Intas Pharma, India
Harry Lam, CTO, JW Therapeutics, China
Victor Li, CEO, Biosyngen, Singapore

10:00
Bridging Cell and Gene Therapy Process Development with Next Generation Automation

  • Where we stand today with “automation”
  • Presence of data and the role of automation in various stages of Process Development
  • CoGs reduction through automation?
  • Digital evolution – linking unit operations across the workflow

Mandy French, Enterprise Technical Scientist, Asia (Cell and Gene Therapy), GE Healthcare Life Sciences 

10:30
Clinical Trials and Manufacturing for TCR-T Product

  • Discovery, development and commercialisation of novel therapies for the treatment of cancer and related conditions
  • Cutting-edge technologies with high affinity specific T-cell receptor (TCR)
  • Manufacturing strategies for TCR-T cells
  • Overcome the challenge of scale up cell therapy products
  • Flexible cell processing and digital connectivity

Li Yi PhD, Chief Scientific Officer, Xiangxue Life Sciences, China

11:00
Morning Networking & Refreshment Break

11:30
A Practical Strategy for a Cell & Gene Digitized Supply Chain

Orchun Thakral, Deputy Managing Director & Head of Sales & Marketing (Asia Pacific), Werum IT Solutions Ltd

12:00
Outlook for Commercial Transfer of Innovative Immune Cell Therapy Technologies in Asia

  • Collaborations to drive immune cell therapy for virus-related tumors
  • Optimising production of materials cell therapy

Victor Li, CEO, Biosyngen, Singapore

12:30
Lunch Break

13:30
Biosimilars in Clinical Practice – Real World Outcomes

  • Biosimilar study design aspects
  • Clinical trial versus real world data
  • Non-medical switching considerations

Daniel Furtner, Medical Director, Regional Medical Affairs, Janssen Asia-Pacific

14:00
Industrialising Gene Therapy

  • Current technologies for manufacturing viral vectors
  • Industrialisation solutions to scale-up manufacturing of viral vectors
  • Cost modeling for industrial solutions

Hyo Jin, Manager, Biotech Integrated Solutions, APAC, Pall

14:30
Indonesia:
Challenges in Stem Cell Production in Indonesia

  • Indonesian regulation updates since 2018
  • Manufacturing challenges and opportunities
  • Processing technology updates
  • Marketing overview and tips sharing in investing in Indonesia
  • Cell harvest case studies in Indonesia

Sandy Qlintang, Deputy Director of Stem Cell and Cancer Institute, PT Kalbe Farma, Indonesia 

15:00
Afternoon Break

15:30
Commercialising Cell Therapy Products- Strategy and Challenges

  • Hospital’s role in cell therapy manufacturing
  • Innovation in commercial operation
  • QbD: Is the current model suitable for cell and gene therapy products?
  • Solution for large-scale C&G therapy manufacturing

Harry Lam, CTO, JW Therapeutics, China

16:00
Addressing Tech Transfer Challenges

  • Overview/background of tech transfer models in a major R&D organisation.
  • Addressing Tech Transfer Challenges through a Master Class Activity:
    • Transforming Scientists to Techno-Commercial Leaders
    • Building an Effective Techno-Commercial Organisation

Sekar Sakthivel, Principal: R&D Programme Management & Business Development || Singapore Bioimaging Consortium || A*STAR Research Entities, Singapore

Co-presenter: Dr Sulin Chen, AVP, A*ccelerate – A*Star

16:45
New Technology Pipeline for CAR-T and Developments in Solid Tumors

  • Overview of global technology development in CART and TCR-T
  • Winning strategies to meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu
  • Cutting-edge science to develop new targeted CAR T therapies for solid tumors
  • Pipeline and technology platform building

Li Zhu PhD, Chief Strategy Officer, Legend, China

17:15
End of Conference Day One
Networking Cocktails

08:30
Morning Coffee

09:00
Chairperson’s Opening Remarks

Terry Nguyen Nguong, Analytical Group Leader, BTI A*Star


OPENING PLENARY
BIOPROCESSING AND COMMERCIALISATION OF CELL AND GENE THERAPY


9:10
Panel Discussion:
Meeting the Demands of the C&GT Products – How Can Technology Help Improve Speed to Market

  • Typical challenges in commercialisation
  • Use cases of process and technology impacting speed to market
  • How do regional facilities need to adapt?
  • Regulatory considerations
  • Supply chain considerations

Moderator:
Tulip Nuwal, Head – Biopharma Business Operations and Excellence, Intas Pharma, India

Panelists:
Harry Lam, CTO, JW Therapeutics, China
Sandy Qlintang, Deputy Director of Stem Cell and Cancer Institute, PT Kalbe Farma, Indonesia
Li Zhu PhD
, Chief Strategy Officer, Legend, China

10:00
Panel Discussion:
Winning the War on Manufacturing Costs and Views on the Money Market

  • Investment in advanced engineering and manufacturing technology to reduce cost of product
  • What’s the next wave of cell and gene therapies?
  • New business models and partnerships
  • Views on managing cost
  • Key takeaways

Moderator:
Terry Nguyen Nguong, Analytical Group Leader, BTI A*Star

Panelists:
Tulip Nuwal, Head – Biopharma Business Operations and Excellence, Intas Pharma, India
Dr Anand Khedkar, Head of R&D, Stelis Biopharma, Singapore
Dayou Liu, Director of Cell Line Development and Molecular Biology, Transcenta, China

10:50
End of Plenary Sessions
Morning Networking & Refreshment Break


OPTIMISING UPSTREAM PROCESSING


11:20
Operational Excellence and Agile Biopharma Operations

  • Capex Planning and procurement to positively impact bioprocess
  • Benchmarking Agile biopharma operations
  • Manufacturing facilities compliance and sustainability
  • Building quality culture in digital age
  • Quality manufacturing best practices

Tulip Nuwal, Head – Biopharma Business Operations and Excellence, Intas Pharma, India

11:50
An Organ-on-a-chip Platform for Research, Drug Development & Personalised Medicine

  • Organ-on-a-chip technology for constructing disease models
  • Phenotypic assays for drug development & preclinical safety testing
  • Clinical diagnostic applications for personalising therapies e.g. immunotherapies

Chee Mun Kuan, CEO, Aim Biotech, Singapore

12:20
Optimizing Cell Line Development

  • Advances in Cell line development and cell culture engineering
  • Challenges of cell line development for antibody production

Matheus Alvin Prawira, Stem Cell and Cancer Institute, PT Kalbe Farma, Indonesia

12:50
Networking Lunch

 14:00
Cell line development platform for fast-to-clinic bioprocess

  • Cell line development is on the critical path of recombinant protein therapeutic development
  • Rationales for establishing a high speed high efficiency cell line development platform
  • Integrated approaches using the cell line development platform to speed up CMC development

Dayou Liu, Director of Cell Line Development and Molecular Biology, Transcenta, China


SCALE-UP AND COMMERCIALISATION STRATEGIES


14:30
Improvement Opportunities in Scale Up and Manufacturing Operations

  • Commercial process development and scaling up
  • Strategies of innovative manufacturing for scaling up production
  • Cost savings on R&D, process scale up and manufacturing operations

Dr Anand Khedkar, Head of R&D, Stelis Biopharma, Singapore

15:00
A Look at Computational Biology and Bioinformatics

  • The impacts data age to bioprocess management and drug discovery
  • Updates on use in the region
  • Computer-aided drug design, machine learning, and pharmainformatics
  • What can we expect in the near future?

Kumar Selvarajoo, Senior Research Scientist @ BioTrans, A*Star, Adjunct Principal Investigator, Synthetic Biology center (SynCITI), NUS, Singapore

15:30
Combined Q&A

16:00
Chairperson’s Summary and End of Conference
With Afternoon refreshments and networking